WO/2016/024328 COMBUSTION DEVICE||WO||18.02.2016|
||PCT/JP2014/071300||NIKO ENGINEERING CO,. LTD.||SUZUKI, Hiroshi|
[Problem] To provide a combustion device for a pellet fuel, the device being able to suppress the accumulation or generation of clinker in a grate part and improve a combustion state of solid fuel having a pellet shape or the like. [Solution] The present invention comprises a fuel transport part 11 that transports a solid fuel, a fuel discharge part 12 that opens vertically upward, and a grate part 13 that combusts the solid fuel. The grate part has a conical fixed grate 13d, a rotating grate 13e that is rotatably disposed on an upper part of the peripheral edge of the fixed grate, and a grate rotary vane 20 that rotates the rotating grate. Clinker is sandwiched and pulverized into small pieces by a rotating grate claw 26 formed on the inside of the rotating grate and a fixed grate claw 27 that protrudes upward from the fixed grate, and the small pieces are removed from the outer peripheral edge of the grate part by a clinker removal device that rotates together with the rotating grate.
WO/2015/193765 SUBSTITUTED DIHYDROISOQUINOLINONE COMPOUNDS||WO||23.12.2015|
||PCT/IB2015/054272||PFIZER INC.||COLLINS, Michael, Raymond|
This invention relates to compounds of general formula (I) in which R1, R2, R3, R4, L, X and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.
WO/2015/191846 N-(CYANOMETHYL)-4-(2-(4-MORPHOLINOPHENYLAMINO)PYRIMIDIN-4-YL)BENZAMIDE HYDROCHLORIDE SALTS||WO||17.12.2015|
||PCT/US2015/035316||GILEAD SCIENCES, INC.||BROWN, Brandon, H.|
The present invention relates to stable novel salt forms of N-(cyanomethyl)-4-(2-(4- morpholinophenylamino)pyrimidin-4-yl)benzamide that are suitable for the preparation of pharmaceutical formulations thereof, and their therapeutic use.
WO/2015/181053 MEDICAL USE||WO||03.12.2015|
||PCT/EP2015/061308||ALMIRALL, S.A.||GODESSART MARINA, Nuria|
The present invention provides a compound, which is an inhibitor of phosphoinositide 3-kinase delta or a pharmaceutically acceptable salt and/or solvate thereof, for use in the treatment of an immunobullous skin disease mediated by autoantibodies by oral administration.
||PCT/EP2015/061312||ALMIRALL, S.A.||GODESSART MARINA, Nuria|
The present invention provides a pharmaceutical composition which comprises (a) a compound which is an inhibitor of phosphoinositide 3-kinase delta or a pharmaceutically acceptable salt and/or solvate thereof, and (b) a corticosteroid.
WO/2015/181052 ADDITION SALTS OF (S)-2-(1-(6-AMINO-5-CYANOPYRIMIDIN-4-YLAMINO)ETHYL)-4-OXO-3-PHENYL-3,4-DIHYDROPYRROLO[1,2-F][1,2,4]TRIAZINE-5-CARBONITRILE||WO||03.12.2015|
||PCT/EP2015/061307||ALMIRALL, S.A.||CARRERA CARRERA, Francesc|
The present invention is directed to novel pharmaceutically acceptable, addition salts of (S)-2-(1-(6-amino-5-cyanopyrimidin-4-ylamino)ethyl)-4-oxo-3-phenyl-3,4- dihydropyrrolo[1,2-f][1,2,4]triazine-5-carbonitrile with sulfonic acid derivatives, in particular with methanesulfonic acid, naphthalene-2-sulfonic acid and para-toluenesulfonic acid, and pharmaceutically acceptable solvates thereof, and their use as Phosphoinositide 3-Kinase (PI3K) inhibitors.
WO/2015/173683 PYRAZOLOPYRIDINES AND PYRAZOLOPYRIMIDINES||WO||19.11.2015|
||PCT/IB2015/053174||PFIZER INC.||COE, Jotham Wadsworth|
A compound having the structure: A compound having the structure (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or pharmaceutically acceptable salt, wherein A and A' are independently C or N, where C may be unsubstituted or substituted by halo or C1-C6 alkyl; R and R0 are independently selected from the group consisting of H, C1-C6 alkyl, hydroxy(C1-C6 alkyl), phenyl(C1-C6 alkyl), and -(CH2)n-W, where W is C3-C8 cycloalkyl, phenyl, naphthyl, 5- or 6-membered heteroaryl or heterocyclic containing 1 -3 N, S and/or 0 atoms, -SO2-R', -NHSO2-R', -NR"SO2-R' and SR', where R' and R" are independently C1-C6 alkyl or C3-C8 cycloalkyl, etc.; wherein each of said alkyl, cycloalkyl, heterocyclic, phenyl, naphthyl or heteroaryl may be unsubstituted or substituted by phenyl, heteroaryl, etc.; or, R and R0 and the N atom to which they are bonded together form a monocyclic or bicyclic heterocyclic ring which may be unsubstituted or substituted by (a) halo, hydroxy, heteroaryl, C1-C6 alkyl, C1-C6 alkoxy, etc., or (b) -(CH2)n-W, where W is C3-C8cycloalkyl, phenyl, etc.; R1 is H, halo or cyano; R2 and R2' are independently H, C1-C6 alkyl, cyano, C1-C6 alkoxy, C1-C6 alkylthio, or C3-C8 cycloalkyl where alkyl, alkoxy, or cycloalkyl is optionally substituted by one or more fluorine atoms; X is a bond, -CO-, -CONH-, -S02-, -SONH-, or -(CH2)m-; R3 is H, C1-C4 alkyl, phenyl, naphthyl, 5- or 6-membered heteroaryl or heterocyclic containing 1 -3 N atoms, a 5-membered heteroaryl or heterocyclic, etc., or (c) 2 O or S atoms and 0-2 N atoms; wherein each of said phenyl, naphthyl, heteroaryl or heterocyclic is optionally substituted by alkyl, 1 substituent -Y-R4 and/or 1 -4 substituents each independently selected from R5; with the proviso that when X is -CO- or -SO2-, R3 is not H; Y is a bond, -(CH2)m- or -O-; R4 is (a) H, C1-C6 alkyl, C3-C8 cycloalkl, halo, oxo, -OR6, -NR7R8, -SR6, -SOR9, -SO2R9, -COR6, -OCOR6, -COOR6, -NR6COR6, -CONR7R8, etc.; (b) phenyl or naphthyl, said phenyl and naphthyl being optionally substituted with 1 -5 substituents selected from C1-C6 alkyl, C3-C8 cycloalkyl, halo, cyano, -OR6, -NR7R8, etc.; or (c) a 3 to 8-membered saturated or partially unsaturated monocyclic heteroaryl, etc.; R6 is H, C1-C6 alkyl or C3-C8 cycloalkyl, etc.; R7 and R8 are each independently H, C1-C6 alkyl or C3-C8 cycloalkyl or are taken together with the nitrogen atom to which they are attached to form a 4-, 5- or 6-membered saturated heterocyclic ring containing 1 -2 nitrogen atoms or 1 nitrogen and 1 oxygen atom, said C1-C6 alkyl is optionally substituted by C3-C8 cycloalkyl, ha lo, etc., and said heterocyclic ring being optionally substituted by one or more C1-C6 alkyl or C3-C8 cycloalkyli groups; R9 is C1-C6 alkyl or C3-C8 cycloalkyl; and, m and n are independently 0, 1, 2 or 3. The invention also relates to pharmaceutically acceptable salts of these compounds and to pharmaceutically acceptable solvates thereof; to compositions containing such compounds; and to the uses of such compounds in the treatment of various diseases, particularly asthma and COPD.
WO/2015/173764 PYRROLIDINE-2,5-DIONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE AS IDO1 INHIBITORS||WO||19.11.2015|
||PCT/IB2015/053557||ITEOS THERAPEUTICS||CROSIGNANI, Stefano|
The present invention relates to compound of Formula (I) or pharmaceutically acceptable enantiomers, salts, solvates or prodrugs thereof. The invention further relates to the use of the compounds of Formula (I) as ID01 inhibitors. The invention also relates to the use of the compounds of Formula I for the treatment and/or prevention of cancer and endometriosis. The invention also relates to a process for manufacturing compounds of Formula (I).
WO/2015/169451 TREATMENT REGIMEN TIACUMICIN COMPOUND||WO||12.11.2015|
||PCT/EP2015/000965||ASTELLAS PHARMA EUROPE LTD||KARAS, Andreas Johannis|
A tiacumicin compound, a stereo-isomer thereof, a polymorph thereof or a pharmaceutically acceptable solvate thereof, and a pharmaceutical composition, containing a tiacumicin compound, a stereo-isomer thereof, a polymorph thereof or a pharmaceutically acceptable solvate thereof, are provided for use in the oral treatment of Clostridium difficile infections (CDI) or Clostridium difficile associated diarrhea or disease (CD AD) in a patient in accordance with a dosage regimen selected from the group consisting of: i. Administering 200 mg of the tiacumicin compound BID for 5 days followed by 5 days of rest and then 200 mg once daily for a further 10 days and ii. Administering 200 mg of the tiacumicin compound BID for 5 days followed by a single 200 mg every other day for 20 days. Further, a method is provided for recovering of gut Bifidobacteria population in a patient, suffering from Clostridium difficile infections (CDI) or Clostridium difficile associated diarrhea or disease (CD AD) and receiving oral treatment with a tiacumicin compound, to 50 to 90 % of the gut Bifidobacteria population prior to administering the tiacumicin compound during days 15-45 after start of the treatment by orally administering the tiacumicin compound to the patient according to a dosage regimen, which is selected from the above-mentioned group.
WO/2015/166373 CYCLOALKYL-LINKED DIHETEROCYCLE DERIVATIVES||WO||05.11.2015|
||PCT/IB2015/052833||PFIZER INC.||BURNS, Aaron Craig|
The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein A, L, D, R1-R15, w, x, y, and z are defined herein. The novel cycloalkyl-linked diheterocycle derivatives that are useful in the treatment of abnormal cell growth, such as cancer, in mammals. The present invention also relates to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in mammals.